References
- To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, Boulet L-P. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. doi:https://doi.org/10.1186/1471-2458-12-204.
- Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, International Study of Asthma and Allergies in Childhood Phase Three Study Group. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64(6):476–483. doi:https://doi.org/10.1136/thx.2008.106609.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:https://doi.org/10.1016/S0140-6736(12)61728-0.
- Sin DD, Man J, Sharpe H, Gan WQ, Man SFP. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292(3):367–376. doi:https://doi.org/10.1001/jama.292.3.367.
- Global Initiative on Asthma (GINA). Global strategy for asthma management and prevention. Available from: http://ginasthma.org/, 2020.
- Price D, Fromer L, Kaplan A, van der Molen T, Román-Rodríguez M. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?Npj Prim Care Resp Med. 2014;24(1):1–9. doi:https://doi.org/10.1038/npjpcrm.2014.23.
- (BTS), B.T.S, BTS/SIGN British guideline on the management of asthma [cited 2017 12 April]. Available from: https://www.brit-thoracic.org.uk/standardsof-care/guidelines/btssign-british-guideline-on-the-management-of-asthma/; 2016.
- Pedersen S, O’Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(39 Suppl):1–34. doi:https://doi.org/10.1111/j.1398-9995.1997.tb05047.x.
- William KH. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009;43(3):519–527. "
- Jaffuel D, Demoly P, Gougat C, Balaguer P, Mautino G, Godard P, Bousquet J, Mathieu M. Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med. 2000;162(1):57–63. doi:https://doi.org/10.1164/ajrccm.162.1.9901006.
- Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J. 1997;10(7):1496–1499. doi:https://doi.org/10.1183/09031936.97.10071496.
- Luijk B, Kempsford RD, Wright AM, Zanen P, Lammers J-WJ. Duration of effect of single-dose inhaled fluticasone propionate on AMP‐induced bronchoconstriction. Eur Respir J. 2004;23(4):559–564. doi:https://doi.org/10.1183/09031936.04.00043504.
- Palmquivst M, Persson G, Lazer L, Rosenberg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10(11):2484–2489. doi:https://doi.org/10.1183/09031936.97.10112489.
- Lötvall J. Pharmacological similarities and differences between β2-agonists. Respir Med. 2001;95:S7–S11. doi:https://doi.org/10.1053/rmed.2001.1139.
- Rajesh V, Augustine J, Divya R, Cleetus M. Inhaled formoterol-fluticasone single inhaler therapy in asthma: real-world efficacy, budget impact, and potential to improve adherence. Can Respir J. 2020;2020:8631316. Article ID 8631316. doi:https://doi.org/10.1155/2020/8631316.
- Marceau C, Lemière C, Berbiche D, Perreault S, Blais L. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol. 2006;118(3):574–581. doi:https://doi.org/10.1016/j.jaci.2006.06.034.
- Delea TE, Stanford RH, Hagiwara M, Stempel DA. Association between adherence with fixed dose combination fluticasone propionate/salmeterol on asthma outcomes and costs. Curr Med Res Opin. 2008;24(12):3435–3442. doi:https://doi.org/10.1185/03007990802557344.
- Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in healthcare. 3rd ed. https://www.york.ac.uk/crd/guidance/ [accessed 15 February 2018]; 2009.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:https://doi.org/10.1371/journal.pmed.1000097.
- Bodzenta-Lukaszyk A, Buhl R, Balint B, Lomax M, Spooner K, Dissanayake S. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012;49(10):1060–1070. doi:https://doi.org/10.3109/02770903.2012.719253.
- Cukier A, Jacob CMA, Rosario Filho NA, Fiterman J, Vianna EO, Hetzel JL, Neis MA, Fiss E, Castro FFM, Fernandes ALG, AIR Brazilian Study Group, et al. Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma. Respir Med. 2013;107(9):1330–1338. doi:https://doi.org/10.1016/j.rmed.2013.06.018.
- Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11(1):28. doi:https://doi.org/10.1186/1471-2466-11-28.
- Aalbers R, Brusselle G, McIver T, Grothe B, Bodzenta-Lukaszyk A. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther. 2012;29(11):958–969. doi:https://doi.org/10.1007/s12325-012-0058-0.
- Usmani OS, Kemppinen A, Gardener E, Thomas V, Konduru PR, Callan C, McLoughlin A, Woodhead V, Brady A, Juniper EF, et al. A randomized pragmatic trial of changing to and stepping down fluticasone/formoterol in asthma. J Allergy Clin Immunol Pract. 2017;5(5):1378–1387. doi:https://doi.org/10.1016/j.jaip.2017.02.006.
- Ghoshal A, Waghray P, Dsouza G, Saluja M, Agarwal M, Goyal A, Limaye S, Balki A, Bhatnagar S, Jain M, et al. Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India. Pulm Pharmacol Ther. 2020;60:101869. doi:https://doi.org/10.1016/j.pupt.2019.101869.
- Kaushal S, Kajal NC, Biswas A. Comparative evaluation of fixed dose combinations of fluticasone/formoterol and budesonide/formoterol in patients of mild-moderate bronchial asthma. Anaesthes Crit Care Med J. 2016;1(2):000110.
- Antilla M, Castro F, Cruz Á, Rubin A, Rosário N, Stelmach R. Efficacy and safety of the single-capsule combination of fluticasone/formoterol in patients with persistent asthma: a non-inferiority trial. J Bras Pneumol. 2014;40(6):599–608. doi:https://doi.org/10.1590/S1806-37132014000600003.
- Wan Yau Ming S, Haughney J, Small I, Wolfe S, Hamill J, Gruffydd-Jones K, Daly C, Soriano JB, Gardener E, Skinner D, et al. Initiating or changing to a fixed-dose combination of Fluticasone propionate/formoterol over fluticasone propionate/salmeterol: a real-life effectiveness and cost impact evaluation. Respir Med. 2017;129:199–206. doi:https://doi.org/10.1016/j.rmed.2017.06.016.
- Price DB, Carter V, Martin J, Gardener EA, Skinner D, Yang S, Hoffman M, Willis JC, Cooper AJ. Comparative safety profile of the fixed-dose combination corticosteroid and long-acting β 2-agonist fluticasone propionate/formoterol fumarate: a 36-month longitudinal cohort study in UK primary care. Drugs. 2020;80(1):47–60. doi:https://doi.org/10.1007/s40265-019-01224-8.
- Dunlop W, Heron L, Fox G, Greaney M. Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthma. Adv Ther. 2013;30(10):933–944. doi:https://doi.org/10.1007/s12325-013-0062-z.
- Farrington E, Saunders A, Heron L, Dunlop W. FP/FORM versus FP/SAL within clinical practice: an updated budget impact analysis in asthma. Adv Ther. 2016;33(5):794–806. doi:https://doi.org/10.1007/s12325-016-0317-6.
- Moragón EM, Delgado J, Ojeda P, Del Llano LP, Collar JM, Antón-Rodriguez C, Martín-Saborido C. Economic evaluation of fluticasone propionate/formoterol (Flutiform®) vs. fluticasone/salmeterol and budesonide/formoterol in Spain. Pulm Ther. 2016;2(2):199–213. doi:https://doi.org/10.1007/s41030-016-0021-3.
- Płoszczuk A, Bosheva M, Spooner K, McIver T, Dissanayake S. Efficacy and safety of fluticasone propionate/formoterolfumarate in pediatric asthma patients: a randomized controlled trial. Ther Adv Respir Dis. 2018;12:175346661877792. 1753466618777924. doi:https://doi.org/10.1177/1753466618777924.
- Emeryk A, Klink R, McIver T, Dalvi P. A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma. Ther Adv Respir Dis. 2016;10(4):324–337. doi:https://doi.org/10.1177/1753465816646320.
- Hanada S, Shirahase K, Sawaguchi H, Muraki M, Tohda Y. The effects of switching from fluticasone/salmeterol aerosol to fluticasone/formoterol aerosol in patients with severe asthma. J Allergy Ther. 2019;10(1):288. doi:https://doi.org/10.4172/2155-6121.1000288.
- Bousquet J, Winchester C, Papi A, Virchow JC, Haughney J, Costa D, Usmani O, Bjermer L, Price D, Global Allergy and Asthma European Network (GA²LEN). Inhaled corticosteroid/long-acting β2-agonist combination therapy for asthma: attitudes of specialists in Europe. Int Arch Allergy Immunol. 2012;157(3):303–310. doi:https://doi.org/10.1159/000329519.
- Leidy NK, Gutierrez B, Lampl K, Uryniak T, O’Brien CD. Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma. 2009;46(10):1006–1012. doi:https://doi.org/10.3109/02770900903301260.
- Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy. 2009;2:63–72. doi:https://doi.org/10.2147/jaa.s4214.
- Hauber AB, Mohamed AF, Johnson FR, Meddis D, Wagner S, O’Dowd L. Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc 2009;30 (2):139–147. doi:https://doi.org/10.2500/aap.2009.30.3205.
- Bender BG, Long A, Parasuraman B, Tran ZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol. 2007;98 (4):322–328. doi:https://doi.org/10.1016/S1081-1206(10)60877-0.
- Singh S, Amin A, Loke Y. Longterm use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229. doi:https://doi.org/10.1001/archinternmed.2008.550.